Bd Singh Biotechnology Pdf Free Download

[Chadwick Bosse]

SinghBiotechnology (SBT) is a biotechnology organization that is in the business of discovering and developing unique and propriety therapeutic agents for the treatment of a variety of diseases (cancers, autoimmune, and ophthalmologic diseases) by leveraging our novel technology platform.

At Singh Biotechnology we use our novel proprietary disruptive technology single domain antibody (sdAb) platform to create miniature antibodies that comprise solely of the variable region and therefore the sdAb is devoid of light chains. Using our proprietary technology we have engineered our sdAbs to be specific & bi-specific, with the ability to cross the cell membrane as well as the blood brain barrier (BBB) to specifically & selectively target intracellular proteins which play an important role in the pathogenesis of a variety of diseases.

With advances in biotechnology, bioremediation has become one of the most rapidly developing fields of environmental restoration, utilizing microorganisms to reduce the concentration and toxicity of various chemical pollutants, such as petroleum hydrocarbons, polycyclic aromatic hydrocarbons, polychlorinated biphenyls, phthalate esters, nitroaromatic compounds, industrial solvents, pesticides and metals. A number of bioremediation strategies have been developed to treat contaminated wastes and sites. Selecting the most appropriate strategy to treat a specific site can be guided by considering three basic principles: the amenability of the pollutant to biological transformation to less toxic products (biochemistry), the accessibility of the contaminant to microorganisms (bioavailability) and the opportunity for optimization of biological activity (bioactivity). Recent advances in the molecular genetics of biodegradation and studies on enzyme-tailoring and DNA-shuffling are discussed in this paper.

Our healthcare equity research is broad in scope and in-depth in content and analysis. In addition to company-specific research, our team publishes sector overviews that seek to identify emerging trends and ways investors can benefit from these changes as well as inherent risks. Our Healthcare research includes healthcare services, healthcare information technology (IT), medical devices, biotechnology, biopharmaceuticals, and specialty pharmaceuticals.

Joel Sendek is a Managing Director and Head of our Life Sciences Equity Research team. Prior to joining Oppenheimer, Joel held CFO positions at four different biotech companies. Prior to that Joel was a senior analyst covering biotechnology at Lazard and subsequently Stifel where he also served as head of the healthcare equity research group. Joel has covered over 100 companies during the course of his sell-side career ranging from profitable large-caps to microcap biotech companies. Joel has been recognized by The Wall Street Journal as an All-Star Analyst with a number one ranking for stock picking. Earlier in his career he worked in business development at Progenics Pharmaceuticals and as an investment banker at Goldman Sachs. He has a biochemistry degree from Rice University.

Andreas Argyrides is an Executive Director and Senior Analyst covering Biotechnology. Prior to joining Oppenheimer, Andreas was Vice President and Senior Analyst covering Biotechnology at Wedbush. Prior to Wedbush, Andreas spent a decade in various roles across the healthcare industry including as healthcare sector specialist and research analyst at a long/short biotech focused hedge fund. Andreas received his BA in History and Economics with honors from New York University.

Leland Gershell is a Managing Director and Senior Analyst covering BioPharmaceuticals. Prior to joining Oppenheimer, Leland was Chief Financial Officer of Capricor Therapeutics and Tonix Pharmaceuticals. Leland also has both sell-side and buy-side experience and began his career on Cowen's biotechnology research team, where he provided sole coverage focused in the small and mid-cap segment. Leland has also authored numerous editorial and review articles and is an inventor on patents for Merck's Zolinza. He earned his MD and Ph.D. in Organic Chemistry from Columbia University and his BA magna cum laude in Chemistry and Asian Studies from Dartmouth College.

Jeff Jones is a Managing Director and Senior Analyst covering Biotechnology. Prior to joining Oppenheimer, Jeff founded and ran One Health Advisors, LLC which provided strategic advisory services for the human and animal biopharma sector. Prior to founding One Health, Jeff had served in numerous roles with biotechnology companies, including Vice President of Business Development at Aratana Therapeutics and COO at Pharmathene. Jeff received an B.A. in Biology from University of Virginia and a Ph.D. in Cell & Molecular Biology from Baylor College of Medicine. He has also completed an M.B.A. at Cornell University, Johnson Graduate School of Management.

Jay Olson is Managing Director and Senior Analyst covering Biotechnology. Prior to joining Oppenheimer, Jay covered SMID-cap names and worked on the Large Cap Pharmaceuticals team at Goldman Sachs for 4 years after 4 years on the #1 II-ranked Large Cap Pharmaceuticals team at Sanford Bernstein. Prior to Wall Street, Jay spent 18 years in the pharmaceutical industry, working mostly for Pfizer in finance, marketing and business development. Jay received an MBA in Finance and an MS in Chemical Engineering both from MIT, and a BS in Chemical Engineering from Tufts University. He also holds the CFA designation.

Steven Lichtman is Managing Director and Senior Analyst for Medical Devices. Steve has been on the sell side following the Medical Devices sector for over 20 years, including 18 as a senior analyst. Prior to joining Oppenheimer to cover Medical Devices, he held that role at JMP Securities and Banc of America Securities. Prior to Banc of America, Steve was the Senior Associate on leading Medical Devices teams at Credit Suisse First Boston and Schroder & Company, Inc. Steve received a B.A. from Duke University in Economics and Public Policy Studies and a M.B.A. from New York University's Stern School of Business.

Michael Wiederhorn is Managing Director and Senior Analyst covering Healthcare Providers and Services. His coverage focuses on managed care, hospitals, nursing homes, home health, hospice, emergency services, and related healthcare services. He has over fifteen years of experience in healthcare consulting and research and in 2013, he was honored as a top ranked Earnings Estimator in Health Care Providers & Services 2013 by Financial Times/Starmine. In addition, in 2009 and 2010, Michael was ranked the #1 brokerage analyst for Medical Care by Forbes Magazine. Prior to entering equity research, Michael was a management consultant at Ernst and Young, serving the healthcare industry. He has a Masters in Health Policy and Management from Harvard University and BA in American History from the University of Pennsylvania.

The site is secure.

The ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Surfactants are amphiphilic compounds which can reduce surface and interfacial tensions by accumulating at the interface of immiscible fluids and increase the solubility, mobility, bioavailability and subsequent biodegradation of hydrophobic or insoluble organic compounds. Chemically synthesized surfactants are commonly used in the petroleum, food and pharmaceutical industries as emulsifiers and wetting agents. Biosurfactants produced by some microorganisms are becoming important biotechnology products for industrial and medical applications due to their specific modes of action, low toxicity, relative ease of preparation and widespread applicability. They can be used as emulsifiers, de-emulsifiers, wetting and foaming agents, functional food ingredients and as detergents in petroleum, petrochemicals, environmental management, agrochemicals, foods and beverages, cosmetics and pharmaceuticals, and in the mining and metallurgical industries. Addition of a surfactant of chemical or biological origin accelerates or sometimes inhibits the bioremediation of pollutants. Surfactants also play an important role in enhanced oil recovery by increasing the apparent solubility of petroleum components and effectively reducing the interfacial tensions of oil and water in situ. However, the effects of surfactants on bioremediation cannot be predicted in the absence of empirical evidence because surfactants sometimes stimulate bioremediation and sometimes inhibit it. For medical applications, biosurfactants are useful as antimicrobial agents and immunomodulatory molecules. Beneficial applications of chemical surfactants and biosurfactants in various industries are discussed in this review.

New and Future Developments in Microbial Biotechnology and Bioengineering: Microbial Biotechnology in Agro-environmental Sustainability describes, in detail, the various roles of microbial resources in the management of crop diseases and how microbes can be used as a source of income for biomass and bioenergy production. In addition, the book covers microbial inoculants as bio-fertilizers to enhance crop productivity, along with degraded land restoration. Users will find the latest information in the field of microbial biotechnology and its further applications in bio-fertilizers, bio-pesticides, its generation as an alternative source of energy, restoration degraded and marginal lands, the mitigation of global warming gases, and more.

Nagendra Kumar Singh (born 15 October 1958) is an Indian agricultural scientist. He is presently a National Professor Dr. B.P. Pal Chair and JC Bose National Fellow at ICAR-National Institute for Plant Biotechnology, Indian Agricultural Research Institute, New Delhi. He was born in a small village Rajapur in the Mau District of Uttar Pradesh, India. He is known for his research in the area of plant genomics, genetics, molecular breeding and biotechnology, particularly for his contribution in the decoding of rice, tomato, wheat, pigeon pea, jute and mango genomes and understanding of wheat seed storage proteins and their effect on wheat quality. He has made significant advances in comparative analysis of rice and wheat genomes and mapping of genes for yield, salt tolerance and basmati quality traits in rice. He is one of the highest cited agricultural scientists from India for the last five years.[1]

3a8082e126